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A. Introduction and aims
The goal of pharmaceutical research is the specific and effective manipulation of disease-modifying targets, which is ideally achieved by small molecules binding to the macromolecule with high affinity. However, it is still a challenging task to inhibit molecular interactions where large surface areas or solvent-exposed binding sites are involved. Macromolecules which could not be efficiently modulated by drug-like small molecules are designated as undruggable proteins. For the inhibition of these targets, a potential solution might be to exploit designed non-natural folded polymers (foldamers), which have emerged as promising materials for biomolecule recognition.
We have investigated two medicinally relevant targets: the immunosuppressant, angiogenic and tumour-nursing Galectin-1 (Gal-1) homodimer, whose inhibition might result in antimetastatic and antiangiogenic drugs; and the synaptotoxic Amyloid β1-42 (Aβ1-42) fibrils and oligomers, which are among the major causative agents of Alzheimer's disease. The inhibition of Gal-1 and Aβ1-42 aggregates is difficult due to their solvent-exposed binding site and the absence of distinct binding pockets.
For studies of the protein-ligand systems, we have used primarily nuclear magnetic resonance (NMR) spectroscopy, which has become a powerful and versatile technique for the characterization of biomolecules and for the detection of molecular interactions. NMR can be exploited in the process of preclinical drug discovery by finding initial hits through screening, supporting lead optimization, fragment-based drug design and obtaining structure-activity relationships (SAR). As opposed to its complementary method X-ray crystallography, NMR can be used to investigate protein-ligand systems in a biologically more relevant medium, solution. Thus, molecular motions, which are confined to the solution phase, can also be captured. The atomic-level structural and dynamic information gained on biomolecules and their complexes from NMR studies can facilitate an understanding of their functions and mechanisms of action and can be utilized in structure-based drug design for the rational improvement of ligands.
Our primary aim was to gain information about our targets by means of NMR spectroscopic techniques, which can promote the structure-based design of new Gal-1-binding compounds and Aβ1-42 inhibitors. We aimed to optimize, validate and improve binding tests which can be efficiently used in an NMR screening process for new inhibitors. In the case of Gal-1, the NMR signal assignment of the labelled protein was a prerequisite for the experiments, so we set out to assign the backbone resonances of 15 N/ 13 C-labelled Gal-1. As a first step, the investigation of the proteins alone and/or in the presence of their natural or literature peptide ligands was targeted.
The goal was to characterize their interactions and to obtain relevant information about the mode of action of the ligands. Finally, we planned to utilize the techniques and structural/dynamic information in drug discovery, most favourably, for the design of foldamer type ligands of the proteins. In order to support and explain the NMR results and test new compounds, the measurements were supplemented with other biophysical techniques and with biological experiments, such as isothermal titration calorimetry (ITC), particle size measurements and enzyme-linked immunosorbent assay (ELISA).
B. Methods
Ligand-detected NMR experiments
The interactions of Gal 
Protein-detected NMR experiments
Protein-detected experiments were used for 
Isothermal titration calorimetry for Aβ1-42 oligomers and foldamers
Isothermal titrations were performed for Aβ1-42 oligomers and foldamers with a Microcal VP-ITC microcalorimeter. The experimental data were fitted to the twoindependent-site binding model.
Other methods
The binding of Tyr-Xxx-Tyr peptides to Gal 
